Teva Pharmaceutical Industries Limited: updates and filings

TEVANYSEHealthcare · Pharmaceutical Preparations

Price

$42.62

November 17, 2026Market cap $49.0B

What Ploutos Investor adds for Teva Pharmaceutical Industries

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 72 daysAround Jan 29, 2027 · for Q4 2026

last Nov 3, 2026next Jan 29, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 3, 2026 latest annualNov 3, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 10, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 3, 2026Results of operations
    Form8-K
  • Nov 2, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 29, 2026Officer or director change
    Form8-K
  • Sep 16, 2026Material agreement entered, new material financial obligation
    Form8-K
  • Sep 14, 2026Other material events
    Form8-K
  • Sep 14, 2026Securities listed on an exchange (amendment)
    Form8-A12B/A
  • Sep 14, 2026One of its securities removed from an exchange (usually a matured note)
    Form25-NSE
  • Sep 11, 2026Regulation FD disclosure, other material events
    Form8-K
  • Sep 3, 2026Other material events
    Form8-K
  • Sep 3, 2026Change to shareholders' rights
    Form8-K
  • Jul 29, 2026Filing
    FormF-6 POS
  • Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Jul 29, 2026Results of operations
    Form8-K
  • May 28, 2026Shareholder vote
    Form8-K
  • Apr 29, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • Apr 29, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Mar 31, 2026Additional annual meeting material
    FormDEFA14A
  • Mar 31, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Mar 31, 2026Annual meeting proxy statement
    FormDEF 14A
  • Feb 18, 2026Filing (amendment)
    Form144/A
  • Feb 17, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Feb 9, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 2, 1996. Of its note and share prospectuses (424B, FWP), the newest 40 of 63.

The full analysis

What do Teva Pharmaceutical Industries's filings show?

The filings are where every one of Teva Pharmaceutical Industries's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.